Charlotte Pahl
Directeur/Membre du Conseil chez Reponex Pharmaceuticals A/S
Fortune : 129 741 $ au 30/04/2024
Profil
Charlotte Pahl currently works as a Director at Reponex Pharmaceuticals A.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2023 | 3 694 210 ( 0,36% ) | 129 741 $ | 30/04/2024 |
Postes actifs de Charlotte Pahl
| Sociétés | Poste | Début |
|---|---|---|
Reponex Pharmaceuticals A/S
 Reponex Pharmaceuticals A/S BiotechnologyHealth Technology Part of Pharma Equity Group A/S, Reponex Pharmaceuticals A/S operates as a Danish clinical stage biopharmaceutical company. The company is based in Hørsholm, Denmark. The company was founded in 2006. The CEO is Soren Nielsen. Reponex Pharmaceuticals was acquired by Pharma Equity Group A/S on March 24, 2023 for $109.83 million. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Reponex Pharmaceuticals A/S
Reponex Pharmaceuticals A/S BiotechnologyHealth Technology Part of Pharma Equity Group A/S, Reponex Pharmaceuticals A/S operates as a Danish clinical stage biopharmaceutical company. The company is based in Hørsholm, Denmark. The company was founded in 2006. The CEO is Soren Nielsen. Reponex Pharmaceuticals was acquired by Pharma Equity Group A/S on March 24, 2023 for $109.83 million. | Health Technology |
